Twist Bioscience Corporation revised earnings guidance for the fiscal year 2024. For the full fiscal year 2024, total revenue is expected to be in the range of $300 million to $304 million compared to previous guidance of $288 million to $293 million, indicating year over year growth of 22% to 24%.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
44.87 USD | -4.55% | -5.40% | +21.73% |
May. 03 | Sector Update: Health Care Stocks Mixed Late Afternoon | MT |
May. 03 | Sector Update: Health Care Stocks Mixed in Afternoon Trading | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+21.73% | 2.74B | |
-3.05% | 90.45B | |
+3.95% | 41.45B | |
-10.51% | 33.57B | |
+60.58% | 25.73B | |
-20.09% | 14.73B | |
-8.92% | 12.82B | |
-11.46% | 11.7B | |
-43.05% | 11.44B | |
+5.17% | 8.79B |
- Stock Market
- Equities
- TWST Stock
- News Twist Bioscience Corporation
- Twist Bioscience Corporation Revises Earnings Guidance for the Fiscal Year 2024